Deflazacort and Fosamprenavir interaction

Deflazacort and Fosamprenavir: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Fosamprenavir (Fosamprenavir Calcium) label · effective 2026-06-30

Major

Coadministration of fluticasone and fosamprenavir calcium/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects.

Drug interactionsby drug classView label on DailyMed
Moderate

Corticosteroid: Dexamethasone ↓ Amprenavir Use with caution.

Drug interactionsby drug classView label on DailyMed
Moderate

Inhaled/nasal steroid: Fluticasone Fosamprenavir calcium: ↑ Fluticasone Use with caution.

Drug interactionsby drug classView label on DailyMed
Minor

Systemic corticosteroid effects including Cushing’s syndrome and adrenal suppression have been reported during postmarketing use in patients receiving ritonavir and inhaled or intranasally administered fluticasone.

Drug interactionsby drug classView label on DailyMed

From the Deflazacort (EMFLAZA) label · effective 2025-11-13

Moderate

Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of EMFLAZA ( 7.1 )

Drug interactionsby drug classView label on DailyMed
Moderate

Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold.

Drug interactionsby drug classView label on DailyMed
Moderate

Therefore, give one third the recommended dosage of EMFLAZA when moderate or strong CYP3A4 inhibitors (e.g., clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with EMFLAZA [see Dosage and Administration ( 2.5 ) and Clinical Pharmacology ( 12.3 )] .

Drug interactionsby drug classView label on DailyMed
Minor

CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 [see Clinical Pharmacology ( 12.3 )] .

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.